Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice

Yanqing Gong1, Erika Hart, Aleksey Shchurin

  • 1Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Department of Cardiovascular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio 44195, USA.

Insights

Plasminogen (Plg) deficiency reduces inflammatory cell migration and abdominal aortic aneurysm development by inhibiting matrix metalloproteinase-9 (MMP-9) activation. Restoring MMP-9 activity rescues these effects, highlighting the Plg/MMP-9 pathway

Area of Science:

  • Cardiovascular Biology
  • Inflammation Research
  • Protease Biochemistry

Background:

  • Inflammation drives cardiovascular diseases, involving leukocyte migration across the extracellular matrix (ECM).
  • Plasminogen (Plg) is an ECM-associated protease that, upon activation to plasmin, degrades ECM proteins and activates matrix metalloproteinases (MMPs).

Purpose of the Study:

  • To investigate the role of Plasminogen (Plg) in inflammatory leukocyte migration and abdominal aortic aneurysm (AAA) development.
  • To elucidate the mechanism involving Plg-mediated activation of matrix metalloproteinase-9 (MMP-9).

Main Methods:

  • Utilized Plasminogen-deficient (Plg(-/-)) mice.
  • Induced peritonitis using thioglycollate injection to assess leukocyte migration.
  • Induced abdominal aortic aneurysm (AAA) via periaortic CaCl2 application.
  • Administered active MMP-9 to Plg(-/-) mice to evaluate rescue effects.

Main Results:

  • Plg(-/-) mice exhibited significantly reduced macrophage trans-ECM migration and diminished MMP-9 activation following peritonitis induction.
  • Plg(-/-) mice were protected from AAA formation, showing reduced macrophage infiltration.
  • Administration of active MMP-9 rescued macrophage migration in Plg(-/-) mice and promoted AAA development.

Conclusions:

  • Plasminogen (Plg) regulates inflammatory macrophage migration and abdominal aortic aneurysm (AAA) development through the activation of matrix metalloproteinase-9 (MMP-9).
  • Targeting the Plg/MMP-9 pathway represents a potential therapeutic strategy for managing inflammatory responses and AAA progression.